Background
Methods
Screening of eligible EC patients
Processing of clinical data
Statistics analysis
Results
Comparison of baseline characteristics between different pathological EC subtypes
Characteristics | UEC | UCCC | USC | UMC | P | Pa | Pb | Pc |
---|---|---|---|---|---|---|---|---|
n | 396 | 34 | 106 | 34 | ||||
Age, mean ± sd | 54.705 ± 8.7763 | 64.088 ± 9.0833 | 61.453 ± 8.5213 | 58 ± 5.1757 | < 0.001 | < 0.001 | < 0.001 | 0.002 |
Menopause, n (%) | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||||
Yes | 235 (59.3%) | 31 (91.2%) | 95 (89.6%) | 32 (94.1%) | ||||
No | 150 (37.9%) | 3 (8.8%) | 10 (9.4%) | 2 (5.9%) | ||||
Unknown | 11 (2.8%) | 0 (0%) | 1 (0.9%) | 0 (0%) | ||||
BMI, median (IQR) | 25.462 (23.422, 28.134) | 26.531 (22.481, 28.125) | 24.654 (22.638, 27.447) | 25.1 (23.508, 26.667) | 0.480 | 0.933 | 0.162 | 0.430 |
Stage, n (%) | < 0.001 | < 0.001 | < 0.001 | < 0.627 | ||||
IV | 2 (0.5%) | 1 (2.9%) | 11 (10.4%) | 0 (0%) | ||||
III | 27 (6.8%) | 6 (17.6%) | 26 (24.5%) | 4 (11.8%) | ||||
II | 6 (1.5%) | 2 (5.9%) | 7 (6.6%) | 1 (2.9%) | ||||
I | 361 (91.2%) | 21 (61.8%) | 59 (55.7%) | 29 (85.3%) | ||||
Unknown | 0 (0%) | 4 (11.8%) | 3 (2.8%) | 0 (0%) | ||||
Myometrial infiltration (> = 1/2), n (%) | < 0.001 | 0.090 | < 0.001 | 0.182 | ||||
Yes | 70 (17.7%) | 4 (11.8%) | 49 (46.2%) | 10 (29.4%) | ||||
No | 297 (75%) | 24 (70.6%) | 50 (47.2%) | 23 (67.6%) | ||||
Unknown | 29 (7.3%) | 6 (17.6%) | 7 (6.6%) | 1 (2.9%) | ||||
Cervix involvement, n (%) | < 0.001 | 0.142 | < 0.001 | 0.073 | ||||
Yes | 18 (4.5%) | 4 (11.8%) | 23 (21.7%) | 3 (8.8%) | ||||
No | 333 (84.1%) | 25 (73.5%) | 80 (75.5%) | 31 (91.2%) | ||||
Unknown | 45 (11.4%) | 5 (14.7%) | 3 (2.8%) | 0 (0%) | ||||
Lymph node metastasis, n (%) | < 0.001 | 0.008 | < 0.001 | 0.053 | ||||
Yes | 19 (4.8%) | 6 (17.6%) | 31 (29.2%) | 2 (5.9%) | ||||
No | 299 (75.5%) | 23 (67.6%) | 62 (58.5%) | 31 (91.2%) | ||||
Unknown | 78 (19.7%) | 5 (14.7%) | 13 (12.3%) | 1 (2.9%) |
Characteristics | UEC | UCCC | USC | UMC | P | Pa | Pb | Pc |
---|---|---|---|---|---|---|---|---|
n | 396 | 34 | 106 | 34 | ||||
Chemotherapy, n (%) | < 0.001 | 0.052 | < 0.001 | < 0.001 | ||||
Yes | 165 (41.7%) | 20 (58.8%) | 81 (76.4%) | 27 (79.4%) | ||||
No | 231 (58.3%) | 14 (41.2%) | 25 (23.6%) | 7 (20.6%) | ||||
Radiotherapy, n (%) | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||||
Yes | 36 (9.1%) | 11 (32.4%) | 43 (40.6%) | 10 (29.4%) | ||||
No | 360 (90.9%) | 23 (67.6%) | 63 (59.4%) | 24 (70.6%) | ||||
OS, n (%) | < 0.001 | < 0.001 | < 0.001 | 1.000 | ||||
Alive | 384 (97%) | 25 (73.5%) | 81 (76.4%) | 33 (97.1%) | ||||
Dead | 12 (3%) | 9 (26.5%) | 25 (23.6%) | 1 (2.9%) | ||||
OS-time(months), median (IQR) | 55.65 (46.42, 71.13) | 38.02 (27.36, 55.58) | 36.83 (25.48, 60.08) | 45.87 (34.88, 62.93) | < 0.001 | < 0.001 | < 0.001 | 0.001 |
PFS, n (%) | < 0.001 | < 0.001 | < 0.001 | 0.227 | ||||
Stable | 380 (96%) | 24 (70.6%) | 75 (70.8%) | 31 (91.2%) | ||||
Recurrent | 9 (2.3%) | 5 (14.7%) | 11 (10.4%) | 2 (5.9%) | ||||
Unknown | 7 (1.8%) | 5 (14.7%) | 20 (18.9%) | 1 (2.9%) | ||||
PFS-time(months), median (IQR) | 55.90 (46.43, 71.13) | 41.10 (31.33, 56.53) | 40.93 (26.53, 62.53) | 45.67 (36.83, 62.97) | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
Comparison of prognosis between different pathological EC subtypes
Characteristics | No | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
Age | 570 | 1.108 (1.075—1.142) | < 0.001 | 1.050 (1.010—1.091) | 0.014 |
Menopause | 570 | < 0.001 | |||
No | 165 | Reference | Reference | ||
Yes | 393 | 10.403 (2.523–42.893) | 0.001 | 2.758 (0.580–13.128) | 0.202 |
Unknown | 12 | 0.000 (0.000–Inf) | 0.996 | 0.000 (0.000–Inf) | 0.997 |
BMI | 255 | 1.025 (0.927–1.134) | 0.627 | ||
Chemotherapy | 570 | 0.857 | |||
No | 277 | Reference | |||
Yes | 293 | 0.949 (0.535–1.682) | 0.857 | ||
Radiotherapy | 570 | 0.448 | |||
No | 470 | Reference | |||
Yes | 100 | 1.320 (0.656–2.655) | 0.436 | ||
Stage | 570 | < 0.001 | |||
I | 470 | Reference | Reference | ||
II | 16 | 2.926 (0.684–12.522) | 0.148 | 1.177 (0.223–6.217) | 0.848 |
III | 63 | 6.122 (3.088–12.137) | < 0.001 | 1.075 (0.218–5.300) | 0.929 |
IV | 14 | 28.979 (12.307–68.238) | < 0.001 | 3.873 (0.936–16.032) | 0.062 |
Unknown | 7 | 17.109 (5.030–58.193) | < 0.001 | 0.489 (0.062–3.839) | 0.496 |
Myometrial infiltration (> = 1/2) | 570 | < 0.001 | |||
No | 394 | Reference | Reference | ||
Yes | 133 | 6.269 (3.300–11.910) | < 0.001 | 3.390 (1.506–7.631) | 0.003 |
Unknown | 43 | 3.764 (1.354–10.463) | 0.011 | 0.791 (0.138–4.539) | 0.793 |
Cervix involvement | 570 | < 0.001 | |||
No | 469 | Reference | Reference | ||
Yes | 48 | 4.992 (2.526–9.866) | < 0.001 | 0.912 (0.390–2.133) | 0.831 |
Unknown | 53 | 2.850 (1.293–6.283) | 0.009 | 4.820 (1.300–17.866) | 0.019 |
Lymph node metastasis | 570 | < 0.001 | |||
No | 415 | Reference | Reference | ||
Yes | 58 | 10.920 (5.600–21.294) | < 0.001 | 3.333 (0.761–14.604) | 0.110 |
Unknown | 97 | 3.401 (1.609–7.191) | 0.001 | 4.153 (1.623–10.626) | 0.003 |
Pathological type | 570 | < 0.001 | |||
UEC | 396 | Reference | Reference | ||
UCCC | 34 | 12.166 (5.106–28.987) | < 0.001 | 12.944 (4.231–39.599) | < 0.001 |
USC | 106 | 10.606 (5.306–21.199) | < 0.001 | 5.958 (2.404–14.765) | < 0.001 |
UMC | 34 | 1.205 (0.156–9.280) | 0.858 | 1.777 (0.209–15.114) | 0.599 |
Characteristics | No | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
Age | 536 | 1.097 (1.054–1.143) | < 0.001 | 1.091 (1.021–1.166) | 0.010 |
Menopause | 536 | 0.027 | |||
No | 162 | Reference | Reference | ||
Yes | 363 | 3.610 (1.084–12.025) | 0.037 | 0.539 (0.109–2.677) | 0.450 |
Unknown | 11 | 0.000 (0.000–Inf) | 0.997 | 0.000 (0.000–Inf) | 0.998 |
BMI | 237 | 0.962 (0.846–1.095) | 0.558 | ||
Chemotherapy | 536 | 0.066 | |||
No | 261 | Reference | Reference | ||
Yes | 275 | 2.125 (0.923–4.892) | 0.076 | 0.609 (0.207–1.791) | 0.368 |
Radiotherapy | 536 | 0.002 | |||
No | 440 | Reference | Reference | ||
Yes | 96 | 3.684 (1.692–8.024) | 0.001 | 1.096 (0.375–3.209) | 0.867 |
Stage | 536 | 0.025 | |||
I | 457 | Reference | Reference | ||
II | 15 | 3.744 (0.861–16.290) | 0.078 | 0.524 (0.073–3.788) | 0.522 |
III | 53 | 4.193 (1.724–10.197) | 0.002 | 0.000 (0.000–Inf) | 0.997 |
IV | 7 | 5.798 (0.759–44.274) | 0.090 | 0.000 (0.000–Inf) | 0.998 |
Unknown | 4 | 0.000 (0.000–Inf) | 0.997 | 0.143 (0.000–Inf) | 1.000 |
Myometrial infiltration (> = 1/2) | 536 | < 0.001 | |||
No | 384 | Reference | Reference | ||
Yes | 114 | 5.562 (2.523–12.262) | < 0.001 | 3.788 (1.255–11.427) | 0.018 |
Unknown | 38 | 0.000 (0.000–Inf) | 0.997 | 0.000 (0.000–Inf) | 0.998 |
Cervix involvement | 536 | < 0.001 | |||
No | 448 | Reference | Reference | ||
Yes | 41 | 9.638 (4.224–21.994) | < 0.001 | 6.253 (1.620–24.138) | 0.008 |
Unknown | 47 | 2.232 (0.635–7.839) | 0.210 | 4.724 (0.929–24.014) | 0.061 |
Lymph node metastasis | 536 | 0.001 | |||
No | 406 | Reference | Reference | ||
Yes | 44 | 5.487 (2.344–12.847) | < 0.001 | 406749342.7904 (0.000–Inf) | 0.997 |
Unknown | 86 | 0.598 (0.138–2.602) | 0.493 | 1.044 (0.204–5.340) | 0.959 |
Pathological type | 536 | < 0.001 | |||
UEC | 389 | Reference | Reference | ||
UCCC | 29 | 10.192 (3.400–30.548) | < 0.001 | 8.696 (1.972–38.354) | 0.004 |
USC | 85 | 6.432 (2.603–15.895) | < 0.001 | 4.131 (1.243–13.729) | 0.021 |
UMC | 33 | 3.070 (0.663–14.228) | 0.152 | 5.356 (0.935–30.692) | 0.060 |
Subgroup analysis based on patients’ clinical stages and postoperative adjuvant therapy
Characteristics | No | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
Age | 486 | 1.150 (1.095–1.207) | < 0.001 | 1.142 (1.078–1.210) | < 0.001 |
BMI | 197 | 1.117 (0.974–1.280) | 0.114 | ||
Chemotherapy | 486 | 0.401 | |||
No | 257 | Reference | |||
Yes | 229 | 0.696 (0.297—1.634) | 0.405 | ||
Radiotherapy | 486 | 0.071 | |||
No | 422 | Reference | Reference | ||
Yes | 64 | 2.551 (0.998–6.520) | 0.050 | 1.382 (0.478–3.998) | 0.550 |
Myometrial infiltration (> = 1/2) | 486 | 0.003 | |||
No | 369 | Reference | Reference | ||
Yes | 83 | 4.721 (2.003–11.131) | < 0.001 | 3.316 (1.075–10.230) | 0.037 |
Unknown | 34 | 1.193 (0.152–9.342) | 0.866 | 0.857 (0.089–8.284) | 0.894 |
Cervix involvement | 486 | 0.061 | |||
No | 421 | Reference | Reference | ||
Yes | 22 | 3.994 (1.155–13.810) | 0.029 | 1.657 (0.392–7.011) | 0.493 |
Unknown | 43 | 2.773 (0.917–8.391) | 0.071 | 4.522 (0.961–21.270) | 0.056 |
Lymph node metastasis | 486 | 0.106 | |||
Unknown | 86 | Reference | |||
No | 400 | 0.457 (0.186–1.121) | 0.087 | ||
Pathological type | 486 | < 0.001 | |||
UEC | 367 | Reference | Reference | ||
UCCC | 23 | 9.390 (2.878–30.641) | < 0.001 | 4.799 (1.121–20.546) | 0.035 |
USC | 66 | 6.059 (2.332–15.745) | < 0.001 | 2.996 (0.852–10.529) | 0.087 |
UMC | 30 | 1.719 (0.217–13.618) | 0.608 | 2.493 (0.278–22.353) | 0.414 |
Characteristics | No | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
Age | 77 | 1.042 (1.000—1.085) | 0.052 | 0.977 (0.915–1.043) | 0.480 |
Menopause | 77 | 0.036 | |||
No | 15 | Reference | Reference | ||
Yes | 58 | 3.336 (0.775–14.360) | 0.106 | 2.256 (0.282–18.033) | 0.443 |
Unknown | 4 | 0.000 (0.000–Inf) | 0.998 | 0.000 (0.000–Inf) | 0.999 |
BMI | 54 | 0.908 (0.757–1.089) | 0.298 | ||
Chemotherapy | 77 | 0.029 | |||
No | 15 | Reference | Reference | ||
Yes | 62 | 0.356 (0.149–0.851) | 0.020 | 0.524 (0.183–1.497) | 0.228 |
Radiotherapy | 77 | 0.002 | |||
No | 42 | Reference | Reference | ||
Yes | 35 | 0.217 (0.073–0.641) | 0.006 | 0.144 (0.044–0.464) | 0.001 |
Myometrial infiltration (> = 1/2) | 77 | 0.128 | |||
No | 25 | Reference | |||
Yes | 50 | 2.292 (0.765–6.870) | 0.139 | ||
Unknown | 2 | 9.137 (0.989–84.410) | 0.051 | ||
Lymph node metastasis | 77 | 0.023 | |||
No | 15 | Reference | Reference | ||
Yes | 58 | 6.157 (0.823–46.057) | 0.077 | 10.666 (1.303–87.304) | 0.027 |
Unknown | 4 | 17.198 (1.535–192.721) | 0.021 | 16.373 (1.302–205.940) | 0.030 |
Pathological type | 77 | < 0.001 | |||
UEC | 29 | Reference | Reference | ||
UCCC | 7 | 3.393 (0.563–20.450) | 0.182 | 5.367 (0.692–41.590) | 0.108 |
USC | 37 | 7.694 (2.206–26.830) | 0.001 | 5.950 (1.613–21.951) | 0.007 |
UMC | 4 | 0.000 (0.000–Inf) | 0.998 | 0.000 (0.000–Inf) | 0.998 |